Drug Trial Radar · NCT06769425
HS-10502 Combination Treatment in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jun 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
157
Planned (sponsor's estimate)
Start
May 7, 2025
Primary completion
May 7, 2026
Study completion Aug 31, 2026
Sponsor
- Lead sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
HS-10502 is a PARP1-specific selective inhibitor. The purpose if this study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10502 Combination Treatment in subjects with advanced solid tumors.
Conditions
- Recurrent Ovarian Cancer
- HER2-negative
- Advanced Breast Cancer
- TNBC
- Advanced Prostate Cancer
- Advanced Gastric Cancer
Interventions
HS-10502 + NHADrug
HS-10502 + NHA
HS-10502 + HS-20093Drug
HS-10502 + HS-20093
HS-10502+ ApatinibDrug
HS-10502+ Apatinib
HS-10502 + HS-20089Drug
HS-10502 + HS-20089
HS-10502 + Platinum + BevacizumabDrug
HS-10502 + Platinum + Bevacizumab
HS-10502 + nab-paclitaxel or Docetaxel or IrinotecanDrug
HS-10502 + nab-paclitaxel or Docetaxel or Irinotecan
HS-10502 + BevacizumabDrug
HS-10502 + Bevacizumab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose (MTD) of HS-10502(Stage 1:Dose escalating stage)Time frame: Cycle 1 (21 days)
- Maximum applicable dose (MAD) of HS-10502(Stage 1:Dose escalating stage)Time frame: Cycle 1 (21days)
- Efficacy of HS-10502: Objective response rate (ORR)(Stage 2: Dose expansion stage)Time frame: From the date of first dose until the date of disease progression or withdrawal from study, approximately 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.